Table III. — Mean and standard deviation (absolute values) for the outcomes of the study (N.=90).
| Outcomes | PBMT-sMF (N.=45) | Placebo (N.=45) |
|---|---|---|
| Degree of pain rating (TPC) | ||
| Stabilization | 13.77 (3.31) | 12.07 (3.63) |
| Baseline | 15.29 (3.08) | 15.20 (2.69) |
| End of treatment | 7.29 (3.99)**** | 12.49 (3.92) |
| Follow-up | 6.22 (4.25)**** | 10.13 (4.66) |
| Impact of fibromyalgia (FIQ 0-100) | ||
| Baseline | 79.68 (11.05) | 77.54 (11.57) |
| End of treatment | 43.89 (22.34)** | 56.71 (18.63) |
| Follow-up | 41.64 (25.86)* | 52.61 (21.57) |
| Pain intensity (VAS 0-100) | ||
| Stabilization | 76.56 (17.51) | 77.37 (11.86) |
| Baseline | 80.64 (13.99) | 74.89 (13.54) |
| End of treatment | 37.80 (23.31)**** | 56.91 (20.31) |
| Follow-up | 34.47 (26.34)** | 49.58 (26.21) |
PBMT-sMF: photobiomodulation therapy combined with static magnetic field; VAS: Visual Analogue Scale; FIQ: Fibromyalgia Impact Questionnaire. Difference of placebo: ****P<0.0001; **P<0.01; *P<0.05.